9 August 2021 - Approval based on unprecedented DAPA-CKD Phase 3 data is the most significant advancement in chronic kidney disease in more than 20 years.

AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose co-transporter 2 inhibitor, has been approved in the European Union for the treatment of chronic kidney disease in adults with and without type 2 diabetes mellitus.

Read AstraZeneca press release